Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press77010.17650/1726-9776-2017-13-4-85-90DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железыCurrent approaches to selection of the 1st line therapy in patients with metastatic hormone-sensitive prostate cancerСовременные подходы к выбору терапии 1-й линии больных метастатическим гормоночувствительным раком предстательной железыAlekseevB. Ya.АлексеевБ. Я.
Russian Federation

3 2nd Botkinskiy Proezd, Moscow 125284

125284 Москва, 2-й Боткинский проезд, 3

AndrianovA. N.АндриановА. Н.
Russian Federation

Build. 1, 51 3rd Parkovaya St., Moscow 105425

Андрей Николаевич Андрианов.

105425 Москва, ул. 3-я Парковая, 51, стр. 1

mailandrianov@gmail.comKaprinA. D.КапринА. Д.
Russian Federation

3 2nd Botkinskiy Proezd, Moscow 125284

125284 Москва, 2-й Боткинский проезд, 3

National Medical Research Radiology Center, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииN.N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiology Center, Ministry of Health of RussiaНаучно-исследовательский институт урологии и интервенционной радиологии им. Н.А. Лопаткина – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России3012201713485901601201816012018https://oncourology.abvpress.ru/oncur/article/view/770

Hormone therapy of metastatic prostate cancer (mPC) has been the “golden standard” of treatment since 1941. However, survival rates in patients with this pathology have remained low. Based on the results of newer studies, early start of docetaxel chemotherapy or antiandrogen abiraterone therapy in combination with standard hormone therapy allows to significantly increase survival of patients with mPC. In this review, data from these studies and advisability of docetaxel and abiraterone at the 1st line therapy of mPC are discussed.

Гормональная терапия метастатического рака предстательной железы (мРПЖ) являлась «золотым стандартом» лечения с 1941 г. Однако показатели выживаемости у пациентов с данной патологией сохранялись на низком уровне. По результатам новых исследований раннее начало химиотерапии доцетакселом или антиандрогенной терапии абиратероном в комбинации со стандартной гормональной терапией позволяет значительно увеличить выживаемость больных мРПЖ. В представленном обзоре освещены данные этих исследований и целесообразность назначения доцетаксела или абиратерона в качестве 1-й линии терапии мРПЖ.

metastatic hormone-sensitive prostate cancerhormone therapychemotherapydocetaxelabirateroneгормоночувствительный метастатический рак предстательной железыгормональная терапияхимиотерапиядоцетакселабиратерон1. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2018. 250 с. [Malignant tumors in Russia in 2016 (morbidity and fatality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2018. 250 p. (In Russ.)].Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2018. 250 с. [Malignant tumors in Russia in 2016 (morbidity and fatality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2018. 250 p. (In Russ.)].2. Состояние онкологической помощи населению России в 2016 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 236 с. [State of oncological care in Russia in 2016. Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P. A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2017. 236 p. (In Russ.)].Состояние онкологической помощи населению России в 2016 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 236 с. [State of oncological care in Russia in 2016. Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P. A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2017. 236 p. (In Russ.)].3. National Cancer Institute. Stat Facts: Prostate Cancer. Available at: https://seer.cancar.gov/statfacts/html/prost.html.National Cancer Institute. Stat Facts: Prostate Cancer. Available at: https://seer.cancar.gov/statfacts/html/prost.html.4. Denmeade S.R., Isaacs J.T. A history of prostate cancer treatment. Nat Rev Cancer 2002;2(5):389–96. DOI: 10.1038/nrc801. PMID: 12044015.Denmeade S.R., Isaacs J.T. A history of prostate cancer treatment. Nat Rev Cancer 2002;2(5):389–96. DOI: 10.1038/nrc801. PMID: 12044015.5. Sharifi N., Dahut W.L., Steinberg S.M. et al. A retrospective study of the time to clinical end-points for advanced prostate cancer. BJU Int 2005;96(7):985–9. DOI: 10.1111/j.1464-410X.2005.05798.x. PMID: 16225513.Sharifi N., Dahut W.L., Steinberg S.M. et al. A retrospective study of the time to clinical end-points for advanced prostate cancer. BJU Int 2005;96(7):985–9. DOI: 10.1111/j.1464-410X.2005.05798.x. PMID: 16225513.6. Ahmed M., Li L.C. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol 2013;20(4):362–71. DOI: 10.1111/iju.12005. PMID: 23163774.Ahmed M., Li L.C. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol 2013;20(4):362–71. DOI: 10.1111/iju.12005. PMID: 23163774.7. Prins G.S., Birch L., Greene G.L. Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 1991;129(6):3187–99. DOI: 10.1210/endo-129-6-3187. PMID: 1954898.Prins G.S., Birch L., Greene G.L. Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 1991;129(6):3187–99. DOI: 10.1210/endo-129-6-3187. PMID: 1954898.8. Karantanos T., Corn P.G., Thompson T.C. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013;32(49):5501–11. DOI: 10.1038/onc.2013.206. PMID: 23752182.Karantanos T., Corn P.G., Thompson T.C. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013;32(49):5501–11. DOI: 10.1038/onc.2013.206. PMID: 23752182.9. Pienta K.J. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 2001;28(4 Suppl 15):3–7. PMID: 11685722.Pienta K.J. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 2001;28(4 Suppl 15):3–7. PMID: 11685722.10. Darshan M.S., Loftus M.S., Thadani-Mulero M. et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011;71(18):6019–29. DOI: 10.1158/0008-5472.CAN-11-1417. PMID: 21799031.Darshan M.S., Loftus M.S., Thadani-Mulero M. et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011;71(18):6019–29. DOI: 10.1158/0008-5472.CAN-11-1417. PMID: 21799031.11. Thadani-Mulero M., Nanus D.M., Giannakakou P. Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res 2012;72(18):4611–5. DOI: 10.1158/0008-5472.CAN-12-0783. PMID: 22987486.Thadani-Mulero M., Nanus D.M., Giannakakou P. Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res 2012;72(18):4611–5. DOI: 10.1158/0008-5472.CAN-12-0783. PMID: 22987486.12. Gan L., Chen S., Wang Y. et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009;69(21):8386–94. DOI: 10.1158/0008-5472.CAN-09-1504. PMID: 19826044.Gan L., Chen S., Wang Y. et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009;69(21):8386–94. DOI: 10.1158/0008-5472.CAN-09-1504. PMID: 19826044.13. Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12. DOI: 10.1056/NEJMoa040720. PMID: 15470213.Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12. DOI: 10.1056/NEJMoa040720. PMID: 15470213.14. Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513–20. DOI: 10.1056/NEJMoa041318. PMID: 15470214.Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513–20. DOI: 10.1056/NEJMoa041318. PMID: 15470214.15. Gravis G., Fizazi K., Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14(2):149–58. DOI: 10.1016/S1470-2045(12)70560-0. PMID: 23306100.Gravis G., Fizazi K., Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14(2):149–58. DOI: 10.1016/S1470-2045(12)70560-0. PMID: 23306100.16. Gravis G., Boher J.M., Joly F. et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU 15 trial. Eur Urol 2016;70(2):256–62.Gravis G., Boher J.M., Joly F. et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU 15 trial. Eur Urol 2016;70(2):256–62.17. Sweeney C.J., Chen Y.H., Carducci M. et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 2015 20;373(8):737–46. DOI: 10.1056/NEJMoa1503747.Sweeney C.J., Chen Y.H., Carducci M. et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 2015 20;373(8):737–46. DOI: 10.1056/NEJMoa1503747.18. Sweeney C., Chen Y., Liu G. et al. Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa). Ann Oncol 2016;27(6):243–65.Sweeney C., Chen Y., Liu G. et al. Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa). Ann Oncol 2016;27(6):243–65.19. James N.D., Sydes M.R., Clarke N.W. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016 19;387(10024):1163–77. DOI: 10.1016/S0140-6736(15)01037-5. PMID: 26719232.James N.D., Sydes M.R., Clarke N.W. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016 19;387(10024):1163–77. DOI: 10.1016/S0140-6736(15)01037-5. PMID: 26719232.20. Tucci M., Bertaglia V., Vignani F. et al. Addition of docetaxel to androgen deprivation therapy for patients with hormonesensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol 2016;69(4):563–73. DOI: 10.1016/j.eururo.2015.09.013. PMID: 26422676.Tucci M., Bertaglia V., Vignani F. et al. Addition of docetaxel to androgen deprivation therapy for patients with hormonesensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol 2016;69(4):563–73. DOI: 10.1016/j.eururo.2015.09.013. PMID: 26422676.21. Andrén O., Widmark A., Fält A. et al. Cabazitaxel followed by androgen deprivation therapy significantly improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer – a randomized, open label, phase III, multicenter trial. ESMO congress 2017, poster session.Andrén O., Widmark A., Fält A. et al. Cabazitaxel followed by androgen deprivation therapy significantly improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer – a randomized, open label, phase III, multicenter trial. ESMO congress 2017, poster session.22. Auchus R.J. The genetics, pathophysyology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am 2001;30(1):101–19. PMID: 11344930.Auchus R.J. The genetics, pathophysyology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am 2001;30(1):101–19. PMID: 11344930.23. Barrie S.E., Potter G.A., Goddard P.M. et al. Pharmacology of novel steroidal inhibitors of cytochrome P450(17)alpha (17-aplha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994;50 (5–6):267–73. PMID: 7918112.Barrie S.E., Potter G.A., Goddard P.M. et al. Pharmacology of novel steroidal inhibitors of cytochrome P450(17)alpha (17-aplha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994;50 (5–6):267–73. PMID: 7918112.24. De Bono J.S., Logothetis C.J., Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995–2005. DOI: 10.1056/NEJMoa1014618. PMID: 21612468.De Bono J.S., Logothetis C.J., Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995–2005. DOI: 10.1056/NEJMoa1014618. PMID: 21612468.25. Fizazi K., Tran N., Fein L. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352–60. DOI: 10.1056/NEJMoa1704174. PMID: 28578607.Fizazi K., Tran N., Fein L. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352–60. DOI: 10.1056/NEJMoa1704174. PMID: 28578607.26. James N.D., de Bono J.S., Spears M.R. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377(4):388–51. DOI: 10.1056/NEJMoa1702900. PMID: 28578639.111-121James N.D., de Bono J.S., Spears M.R. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377(4):388–51. DOI: 10.1056/NEJMoa1702900. PMID: 28578639.111-121